⚖️

Tirzepatide

Also known as: Mounjaro, Zepbound

Well ResearchedWeight ManagementProvider Rx Required

How It Works

Dual GIP/GLP-1 receptor agonist. Combines two incretin pathways for enhanced metabolic effects. Superior weight loss and glycemic control vs GLP-1 alone.

What It's Used For

Weight lossType 2 diabetesMetabolic healthInsulin resistance

Administration

Route: Subcutaneous injection
Typical Cycle: Long-term use

Safety & Side Effects

Possible Side Effects

  • Nausea
  • Diarrhea
  • Constipation
  • Vomiting
  • Abdominal pain
  • Injection site reactions

Contraindications

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pancreatitis history
  • Pregnancy

Research Summary

FDA-approved dual GIP/GLP-1 agonist. SURMOUNT-1 showed up to 22.5% body weight reduction at highest dose. Currently the most effective pharmaceutical weight loss agent.

References

  • Jastreboff AM et al. N Engl J Med. 2022 (SURMOUNT-1)

Legal & Availability

FDA-approved (prescription)

This peptide requires a prescription from a licensed provider.

Dosing Protocol

Standard: 2.5mg-15mg weekly (titrated up)

Frequency: Once weekly

Timing: Same day each week

Notes: Titrate: 2.5mg x4wk → 5mg x4wk → 7.5mg x4wk → 10mg x4wk → 12.5mg x4wk → 15mg

🔒

Unlock Full Dosing Protocol

Specific dosing, frequency, timing, cycling schedules, and stacking guidance are available with a BioRoot AI Pro subscription.

Stacks Well With

Full stacking protocols and cycling schedules available with Pro subscription.

Is Tirzepatide Right for You?

Our AI analyzes your symptoms, labs, and medical history to determine if this peptide fits your protocol — and at what dose.

Is Tirzepatide right for you?

Get a free personalized analysis based on your symptoms and goals — delivered to your inbox.

This information is for educational purposes only and is not medical advice. Do not use any peptide without consulting a qualified healthcare provider. BioRoot AI is a clinical decision support tool — not a medical provider.